HUTCHMED (China) LimitedHCM

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · China · hutch-med.com

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Headquartered in Hong Kong, its first three in-house discovered medicines are marketed in China, with the first also approved in the US, Europe and Japan. Listed on Nasdaq and AIM (HCM) and on HKEX (13).

Key ratios

Operating cash flow growth

-99.8%TTM

2024 -99.8%

EPS growth

-96.2%TTM

2025 1200.0%2024 -66.3%

FCF / Sales

-14.4%2025

2024 -2.8%2023 22.3%

Net margin

3.3%TTM

2025 83.3%2024 6.0%2023 12.0%

ROA

-1.2%TTM

2025 -1.6%2024 -2.1%2023 1.0%

ROE

1.5%TTM

2025 45.3%2024 5.0%2023 14.7%

Revenue growth

-13.0%2025

2024 -24.8%2023 96.5%

Recent news

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy 2026-09-03 · GlobeNewswire HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS Plus TAGRISSO in EGFR-mutated Lung Cancer 2026-08-31 · GlobeNewswire HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma 2026-08-28 · GlobeNewswire HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® 2026-08-17 · GlobeNewswire

Track HCM in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer